Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524914 | 0.92 | EPHX1 (0.38) | EPHX1MAPTALDH1A1KDM4ENPC1 | |
| SCHEMBL1690524 | 0.92 | EPHX1 (0.38) | EPHX1MAPTALDH1A1KDM4ENPC1 | |
| SCHEMBL14942466 | 0.92 | EPHX1 (0.38) | EPHX1MAPTALDH1A1KDM4ENPC1 | |
| SCHEMBL14336925 | 0.89 | MAPT (0.33) | MAPTALDH1A1 | |
| SCHEMBL14227529 | 0.82 | CHRNB2 (0.43) | EPHX1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL16556334 | 0.82 | CHRNB2 (0.43) | EPHX1MAPTALDH1A1KDM4EALOX15 | |
| SCHEMBL13165462 | 0.81 | MAPT (0.38) | MAPTALDH1A1ALOX15 | |
| SCHEMBL2617044 | 0.81 | MAPT (0.38) | MAPTALDH1A1ALOX15 | |
| SCHEMBL76462 | 0.81 | — | — | |
| SCHEMBL13165512 | 0.81 | MAPT (0.38) | MAPTALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019202884-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, LIQUID CRYSTAL ELEMENT, POLYMER, AND COMPOUND | JSR株式会社 | 2019-10-24 | — | — | WO | disclosed |
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2722380-A2 | Liquid crystal medium, method for the stabilisation thereof and liquid crystal display | Merck Patent GmbH (DE) | 2014-04-23 | — | — | EP | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8426626-B2 | Compound having asymmetric carbon atom, oxidation-reduction reaction causing portion, and liquid crystal substituent | FUJIFILM CORPORATION (JP) | 2013-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | EPHX1 3837/4885MAPT 4574/4885ALDH1A1 4703/4885 |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | EPHX1 3837/4885MAPT 4574/4885ALDH1A1 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.